Company / Financials
AXIM BIOTECHNOLOGIES, INC. Financials
FY2011-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$39.5K
FY2023 · +345.3% YoY
Net Income
-$8.1M
FY2023 · -29.1% YoY
Profit Margin
-20395.0%
FY2023 · net income / revenue
ROE
-
FY2023 · return on equity
Total Assets
$4.1M
FY2023
Total Debt
-
FY2023
Equity
-$7.7M
FY2023
ROA
-195.6%
FY2023 · return on assets
Statement paths
Financial highlights
Key Data Points
- Altman Z-Score -18.18 (distress zone, below 1.23 threshold)
- Piotroski F-Score: 2/9 criteria passed
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$39.5K+345.3% YoYNet Income HistoryProfit after all expenses and taxes-$8.1M-29.1% YoYGross Profit HistoryRevenue minus cost of goods sold-Cost of Revenue HistoryDirect costs of producing goods and services sold-Operating Income HistoryProfit from core business operations before interest and taxes-$2.8M+40.9% YoYSG&A Expense HistorySelling, general, and administrative expenses$2.2M-45.2% YoYR&D Expense HistoryResearch and development spending$125.5K-18.3% YoYInterest Expense HistoryCost of borrowing and debt obligations$140.0K-46.5% YoYIncome Tax HistoryTotal income tax expense$0EPS (Basic) HistoryBasic earnings per share-$0.04-133.3% YoY